Francesco Lo-Coco

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi request reprint MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis
    Paolo Lunghi
    Department of Clinical Sciences, Section of Hemato Oncology, University of Parma, Via Gramsci 14, 43100 Parma, Italy
    Blood 107:4549-53. 2006
  2. ncbi request reprint Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia
    F Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Università Tor Vergata Via Montpellier, 1 00133 Rome, Italy
    Curr Top Microbiol Immunol 313:145-56. 2007
  3. ncbi request reprint Understanding the molecular pathogenesis of acute promyelocytic leukemia
    Francesco Lo-Coco
    Department of Biomedicine and Prevention, University of Rome Tor Vergata and Fondazione Santa Lucia, Rome, Italy Electronic address
    Best Pract Res Clin Haematol 27:3-9. 2014
  4. ncbi request reprint What is the standard regimen for patients with acute promyelocytic leukemia?
    Francesco Lo-Coco
    Department of Biomedicine and Prevention, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Curr Hematol Malig Rep 9:138-43. 2014
  5. ncbi request reprint Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    Francesco Lo-Coco
    Dipartimento di Biomedicina e Prevenzione, Universita Tor Vergata, Rome, Italy
    N Engl J Med 369:111-21. 2013
  6. doi request reprint Acute leukemia in women
    Francesco Lo-Coco
    Department of Biopathology, University of TorVergata, Rome, Italy
    Womens Health (Lond Engl) 6:239-49. 2010
  7. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Universita Tor Vergata, Rome, Italy
    Blood 104:1995-9. 2004
  8. ncbi request reprint Acute promyelocytic leukemia: recent advances in diagnosis and management
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata, Rome, Italy
    Semin Oncol 35:401-9. 2008
  9. doi request reprint Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00161 Rome, Italy
    Haematologica 93:1017-24. 2008
  10. ncbi request reprint Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNA
    Francesco Lo Coco
    Ematologia, Dipartimento di Biopatologia Umana, Universita La Sapienza di Roma, Rome, Italy
    Haematologica 90:291A. 2005

Detail Information

Publications88

  1. ncbi request reprint MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis
    Paolo Lunghi
    Department of Clinical Sciences, Section of Hemato Oncology, University of Parma, Via Gramsci 14, 43100 Parma, Italy
    Blood 107:4549-53. 2006
    ..Combined treatment resulted in the induction of the proapoptotic p53/p73 target gene p53AIP1 (p53-regulated apoptosis-inducing protein 1) and greatly enhanced the apoptosis of treated cells...
  2. ncbi request reprint Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia
    F Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Università Tor Vergata Via Montpellier, 1 00133 Rome, Italy
    Curr Top Microbiol Immunol 313:145-56. 2007
    ..The more accurate and reproducible real-time PCR method to detect at quantitative levels the PML/RARalpha hybrid will likely provide better inter-laboratory standardization and trial results comparison in the near future...
  3. ncbi request reprint Understanding the molecular pathogenesis of acute promyelocytic leukemia
    Francesco Lo-Coco
    Department of Biomedicine and Prevention, University of Rome Tor Vergata and Fondazione Santa Lucia, Rome, Italy Electronic address
    Best Pract Res Clin Haematol 27:3-9. 2014
    ..While transforming oncogenic potential of PML-RARα has been described extensively, the mechanistic events important for the formation of t(15;17) have been taken from the model of Therapy-related APL (t-APL). ..
  4. ncbi request reprint What is the standard regimen for patients with acute promyelocytic leukemia?
    Francesco Lo-Coco
    Department of Biomedicine and Prevention, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Curr Hematol Malig Rep 9:138-43. 2014
    ....
  5. ncbi request reprint Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    Francesco Lo-Coco
    Dipartimento di Biomedicina e Prevenzione, Universita Tor Vergata, Rome, Italy
    N Engl J Med 369:111-21. 2013
    ..Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity...
  6. doi request reprint Acute leukemia in women
    Francesco Lo-Coco
    Department of Biopathology, University of TorVergata, Rome, Italy
    Womens Health (Lond Engl) 6:239-49. 2010
    ..Finally, we address the issue of therapy-related acute leukemia in the category of women who are survivors of breast and ovarian cancer...
  7. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Universita Tor Vergata, Rome, Italy
    Blood 104:1995-9. 2004
    ..These data indicate that GO is highly effective as a single treatment for patients with molecularly relapsed APL including those with very advanced disease...
  8. ncbi request reprint Acute promyelocytic leukemia: recent advances in diagnosis and management
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata, Rome, Italy
    Semin Oncol 35:401-9. 2008
    ....
  9. doi request reprint Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00161 Rome, Italy
    Haematologica 93:1017-24. 2008
    ..The aim of this study was to verify this prospectively in a large group of patients...
  10. ncbi request reprint Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNA
    Francesco Lo Coco
    Ematologia, Dipartimento di Biopatologia Umana, Universita La Sapienza di Roma, Rome, Italy
    Haematologica 90:291A. 2005
  11. doi request reprint Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata of Rome, Via Montpellier 1, Rome, Italy
    Blood 116:3171-9. 2010
    ..Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group...
  12. doi request reprint Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression
    Giuseppe Zardo
    San Raffaele Bio medical Park Foundation, Rome, Italy
    Blood 119:4034-46. 2012
    ....
  13. ncbi request reprint Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts
    Roberta Riccioni
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy
    Stem Cells 25:1862-71. 2007
    ..The autocrine angiopoietin/Tie-2 axis may represent a promising therapeutic target to improve the outcome of patients with monocytic AML. Disclosure of potential conflicts of interest is found at the end of this article...
  14. doi request reprint Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin
    Tiziana Ottone
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Br J Haematol 161:533-40. 2013
    ..Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML...
  15. ncbi request reprint Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia
    Francesco Fazi
    San Raffaele Bio medical Park Foundation, Rome, Italy
    Blood 109:4432-40. 2007
    ..Finally, RARbeta2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis...
  16. ncbi request reprint Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein
    Francesco Fazi
    Department of Histology and Medical Embryology, University La Sapienza, Rome, 00161, Italy
    Cancer Cell 12:457-66. 2007
    ..Here, we identify an additional action for a leukemia fusion protein linking the epigenetic silencing of a microRNA locus to the differentiation block of leukemia...
  17. ncbi request reprint Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation
    Emanuele Ammatuna
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata via Montpellier, Rome, Italy
    Ann Hematol 86:355-61. 2007
    ..We conclude that this non-isotopic and rapid assay amenable to automation may be adopted in routine genetic diagnosis of CMDs as well as for initial screening of thrombocytosis of unknown nature...
  18. ncbi request reprint Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci
    Syed Khizer Hasan
    Department of Biopathology, University of Rome Tor Vergata, Rome, Italy
    Genes Chromosomes Cancer 49:726-32. 2010
    ..Biased distribution of DNA breakpoints at both PML and RARA loci suggest the existence of different pathogenetic mechanisms in t-APL as compared with de novo APL...
  19. pmc An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia
    Tiziana Ottone
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
    J Mol Diagn 10:212-6. 2008
    ..This method is convenient and easily applicable in countries with limited resources and no access to real-time quantitative PCR-based technologies...
  20. ncbi request reprint Molecular characterization of paediatric idiopathic hypereosinophilia
    Maria Cristina Rapanotti
    Department of Laboratory Medicine, Policlinico Tor Vergata, Rome, Italy
    Br J Haematol 151:440-6. 2010
    ..IGH rearrangement was observed to be a frequent molecular feature of pHES and may precede B-cell clonal expansion and evolution into B-cell malignancies in children...
  21. doi request reprint Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Res 37:383-5. 2013
    ..001), with a 5-year CIR of 29.6% compared to 12% (p=0.03). APL patients with delayed CR should be more closely monitored during follow-up for early identification of relapse and prompt administration of pre-emptive salvage therapy...
  22. doi request reprint Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia
    Girish Chander Gaur
    Department of Biopathology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Ann Hematol 91:1855-60. 2012
    ..In adult APL, WT1 gene mutational and polymorphic profile shows similarities with pediatric AML rather than with adult AML...
  23. ncbi request reprint Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis
    Ugo Testa
    Departments of Hematology and Oncology, Virology, and Immunology, Istituto Superiore di Sanita, Rome, Italy
    Blood 100:2980-8. 2002
    ..These findings suggest that in AML, deregulated expression of IL-3Ralpha may contribute to the proliferative advantage of the leukemic blasts and, hence, to a poor prognosis...
  24. pmc Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era
    Safaa M Ramadan
    Department of Biopathology, University of Rome Tor Vergata, Italy
    Haematologica 97:1731-5. 2012
    ..6%. In conclusion, allogeneic transplant is effective in advanced acute promyelocytic leukemia in the all-trans-retinoic acid and arsenic trioxide era, and should be considered once relapse is diagnosed...
  25. pmc Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression
    Ugo Testa
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, University La Sapienza, Rome, Italy
    Blood 106:2527-9. 2005
    ..These observations support a potential use of DT388IL-3[K116W] in the treatment of refractory AMLs and provide a simple biochemical parameter for the selection of eligible patients...
  26. ncbi request reprint Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
    Giuseppe Cimino
    Department of Cellular Biotechnology and Hematology, University of Rome La Sapienza, Rome, Italy
    Cancer Res 66:8903-11. 2006
    ..Further studies are needed to evaluate whether VPA-ATRA treatment by reprogramming differentiation of the leukemic clone might improve the response to chemotherapy in leukemia patients...
  27. pmc Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
    Syed Khizer Hasan
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Blood 112:3383-90. 2008
    ..This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this subtype of leukemia after exposure to this agent...
  28. pmc Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis
    Emanuele Ammatuna
    Department of Biopathology, University Tor Vergata, Rome, Italy
    Haematologica 96:621-5. 2011
    ....
  29. doi request reprint Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation
    Tiziana Ottone
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
    Genes Chromosomes Cancer 48:213-21. 2009
    ..This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs...
  30. doi request reprint Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Blood 119:49-54. 2012
    ..99, in overweight/obese vs under/normal weight patients, P = .049). An increased BMI at diagnosis is associated with a higher risk of developing differentiation syndrome and disease relapse in APL patients treated with AIDA protocols...
  31. doi request reprint Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations
    Roberta Riccioni
    Department of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Br J Haematol 153:33-42. 2011
    ..Addition of FLT3 Ligand to human CD34(+) or monocytic cells stimulated CD123 and TRAIL-R expression. These findings are of potential value for the development of new therapeutic strategies...
  32. pmc Transcriptional silencing of the ETS1 oncogene contributes to human granulocytic differentiation
    Valentina Lulli
    Dept of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy
    Haematologica 95:1633-41. 2010
    ..This study focuses on the role of Ets-1 during granulocytic differentiation of NB4 promyelocytic and HL60 myeloblastic leukemia cell lines induced by all-trans retinoic acid...
  33. ncbi request reprint TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL
    Roberta Riccioni
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Haematologica 90:612-24. 2005
    ..However, many cancer cells are resistant to apoptosis induction by TRAIL. The present study was designed to evaluate the sensitivity to TRAIL-induced apoptosis in acute myeloblastic leukemias (AML)...
  34. doi request reprint Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia
    Saquib Ashraf
    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Ann Hematol 92:1319-23. 2013
    ..Our ASO-PCR method appears useful for routine diagnostic screening of these prognostically relevant alterations in AML and may be conveniently included in the diagnostic workup...
  35. ncbi request reprint M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis
    Roberta Riccioni
    Department of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Br J Haematol 139:194-205. 2007
    ..The findings of the present study, further support the development of Bortezomib as an anti-leukaemic drug and provide simple tools to predict the sensitivity of AML cells to this drug...
  36. ncbi request reprint Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease
    Massimo Breccia
    Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161 Rome, Italy
    Expert Opin Pharmacother 13:1031-43. 2012
    ..Moreover, ATO has been included in the design of several front-line studies, with the aim to reduce therapy-related toxicity while maintaining the potential of cure...
  37. ncbi request reprint The importance of molecular monitoring in acute promyelocytic leukaemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Best Pract Res Clin Haematol 16:503-20. 2003
    ..The introduction of quantitative PCR through automated technologies is likely to further improve standardization of the method and comparison of results obtained in the context of large clinical trials...
  38. doi request reprint Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
    Francesco Buccisano
    Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy
    Blood 119:332-41. 2012
    ..A comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, should promote advances in development of personalized therapeutic approaches...
  39. doi request reprint Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia
    Syed Khizer Hasan
    Department of Biopathology, University Tor Vergata, Via Montpellier 1, Rome, Italy
    Clin Lymphoma Myeloma Leuk 10:S139-43. 2010
    ..Finally, optimization of therapy and minimization of toxicity is feasible in this disease through careful monitoring of residual disease using polymerase chain reaction-based approaches targeting the PML-RARA fusion gene...
  40. ncbi request reprint Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Best Pract Res Clin Haematol 16:653-70. 2003
    ..Further, we discuss briefly the clinical utility of detecting these alterations for prognostic assessment and evaluation of response to treatment...
  41. ncbi request reprint GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children
    Anna Maria Testi
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Blood 106:447-53. 2005
    ..A white blood cell (WBC) count at diagnosis of greater than 10 x 10(9)/L had a significant impact on EFS (59% vs 83% at 10 years). These results highlight the efficacy and feasibility of the AIDA protocol in the pediatric APL population...
  42. ncbi request reprint Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies
    Maria C Petti
    Hematology Section, Regina Elena Cancer Institute, Department of Cellular Biotechnology, University La Sapienza, Rome, Italy
    Blood 100:1065-7. 2002
    ..Our findings indicate that the maturation block may be overcome and terminal differentiation obtained in this leukemia subset and support the view that sensitivity/refractoriness of this form to ATRA should be revisited...
  43. ncbi request reprint Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23)
    Syed Khizer Hasan
    Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy Laboratorio di Neuro Oncoematologia, Fondazione Santa Lucia, Rome, Italy
    Genes Chromosomes Cancer 53:248-54. 2014
    ..This study further supports the evidence that MLL breakpoints in therapy-related acute leukemia with MLL-AFF1 are clustered in the telomeric half of the breakpoint cluster region that contains topo II recognition sites...
  44. pmc MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status
    Isabella Faraoni
    Laboratory of Neuro Oncohematology, Santa Lucia Foundation, Rome, Italy
    J Hematol Oncol 5:26. 2012
    ..Three types of normalization were used for the data validation...
  45. ncbi request reprint Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin
    Francesco Lo Coco
    Department of Biopathology, University of Tor Vergata, Rome, Italy
    Clin Adv Hematol Oncol 4:57-62, 76-7. 2006
    ..This review summarizes the mechanism of action and toxicity profile of gemtuzumab as well as the published experience with this compound in patients with newly diagnosed and relapsed APL...
  46. ncbi request reprint Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo
    Francesco Fazi
    San Raffaele Bio medical Science Park of Rome, Rome, Italy
    Oncogene 24:1820-30. 2005
    ..These results extend the rationale for chromatin-targeted treatment in APL and RA-resistant leukemias...
  47. ncbi request reprint Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia
    Luca Maurillo
    Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    J Clin Oncol 26:4944-51. 2008
    ..The effects of autologous (AuSCT) or allogeneic stem-cell transplantation (SCT) are still under evaluation. Minimal residual disease (MRD) states may be essential for assigning patients to therapy-dependent risk categories...
  48. ncbi request reprint Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4
    Sergio Bernardini
    Department of Internal Medicine, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy
    Ann Hematol 85:681-7. 2006
    ..Further investigation is warranted to find a way to interfere with this balance, whenever it might represent a mechanism of drug resistance...
  49. pmc Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia
    Antonella Conforti
    Department of Pediatric Hematology Oncology, IRCCS Bambino Gesù Children s Hospital, Rome, Italy
    PLoS ONE 8:e76989. 2013
    ..Our findings indicate that ALL-MSCs display reduced ability to proliferate and to support long-term hematopoiesis in vitro. ALL-MSCs isolated at diagnosis do not differ from those obtained during treatment. ..
  50. ncbi request reprint Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC
    Emanuele Ammatuna
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
    Clin Chem 51:2165-7. 2005
  51. doi request reprint Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
    Massimo Breccia
    Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161 Roma, Rome, Italy
    Expert Opin Biol Ther 11:225-34. 2011
    ..Gemtuzumab ozogamicin (GO) is a calicheamicin-conjugated mAb directed against CD33, a surface antigen highly expressed on APL blasts. GO has been shown to be effective in this disease and better tolerated than conventional chemotherapy...
  52. ncbi request reprint Idiopathic hypereosinophilic syndrome: a case evolving in B-lymphoblastic lymphoma
    Maria Cristina Rapanotti
    Dipartimento di Medicina Interna, Facolta di Medicina e Chirurgia, University Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
    Leuk Res 29:975-9. 2005
    ..Here, we describe a case of HES that preceded the occurrence of a high-grade B-lymphoblastic lymphoma in which clonal evolution has been demonstrated at the molecular level...
  53. doi request reprint ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
    Massimo Breccia
    aDepartment of Hematology, Sapienza University, Rome bDepartment of Biomedicine and Prevention, University Tor Vergata cLaboratory of Neuro Oncohematology, Santa Lucia Foundation, Rome, Italy
    Curr Opin Hematol 21:95-101. 2014
    ..The role of ATO in front-line therapy of APL is under investigation...
  54. pmc Acute myeloid leukemia developing in patients with autoimmune diseases
    Safaa M Ramadan
    Department of Medical Oncology, NCI Cairo University, 11796 Cairo, Egypt
    Haematologica 97:805-17. 2012
    ..A better understanding of the molecular defects in autoimmune disease patients who develop acute leukemia will lead to a better understanding of the association between these two diseases entities...
  55. ncbi request reprint Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience
    Alessandro Pulsoni
    Cellular Biotechnology and Hematology Department, La Sapienza University, Via Benevento 6, 00161 Rome, Italy
    Blood 100:1972-6. 2002
    ..In spite of important clinical differences (older age and poorer performance status), the APL-st group responded as well as the de novo APL group to upfront ATRA plus chemotherapy, probably reflecting genetic similarity...
  56. ncbi request reprint Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients
    M Christina Cox
    Department of Hematology, S Eugenio Hospital, University of Tor Vergata, Rome, Italy
    Am J Clin Pathol 122:298-306. 2004
    ..Moreover, these cases should be readily distinguishable from 11q23+/MLL+ cases. We recommend that karyotypic analysis always be complemented by molecular or FISH methods to unravel MLL rearrangements...
  57. ncbi request reprint Podocalyxin is expressed in normal and leukemic monocytes
    Roberta Riccioni
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161, Rome, Italy
    Blood Cells Mol Dis 37:218-25. 2006
    ..These observations suggest a possible relationship between the monocytic lineage and podocytes...
  58. ncbi request reprint Molecular monitoring of hematologic malignancies: current and future issues
    Francesco Lo Coco
    Department of Cellular Biotechnologies and Hematology, Universita La Sapienza, Rome, Italy
    Semin Hematol 39:14-7. 2002
    ..There is a real need for an international consensus on standardization of PCR techniques...
  59. ncbi request reprint Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
    Roberto Latagliata
    Department of Human Biotechnologies and Hematology, University La Sapienza of Rome, Cattedra di Ematologia, Via Benevento 6 00161, Rome, Italy
    Blood 99:822-4. 2002
    ....
  60. doi request reprint Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia
    Francesco Buccisano
    Hematology, Fondazione Policlinico Tor Vergata, Viale Oxford 81, Rome, Italy
    Blood 116:2295-303. 2010
    ..001 for all comparisons). In AML, the integrated evaluation of baseline prognosticators and MRD improves risk-assessment and optimizes postremission therapy...
  61. ncbi request reprint Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore and Dipartmento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Blood 100:2703-7. 2002
    ..003). In conclusion, individuals with GSTM1 or GSTT1 deletions (or deletions of both) may have an enhanced resistance to chemotherapy and a shorter survival...
  62. doi request reprint Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes
    S K Hasan
    Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Neurology 76:1059-65. 2011
    ..We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ)...
  63. ncbi request reprint Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes
    Francesco Buccisano
    Department of Biopatologia e Diagnostica per Immagini, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Eur J Haematol 80:107-14. 2008
    ..An aberrant pattern of expression of L-selectin and intercellular adhesion molecule 1 (ICAM1) may characterise CD34+ blast cells in myelodysplastic syndromes (MDS) and secondary acute myeloid leukaemia (sAML)...
  64. ncbi request reprint Advances in the understanding and management of acute promyelocytic leukemia
    Franco Mandelli
    Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Rev Clin Exp Hematol 6:60-71; discussion 86-7. 2002
    ....
  65. doi request reprint The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia
    Giovanni Del Poeta
    Department of Haematology, Ospedale S Eugenio, University Tor Vergata, Rome, Italy
    Br J Haematol 149:383-7. 2010
    ..35 subset showed a very high CR rate (96%), very long OS (P = 0.00005) and disease-free survival (P = 0.004). The favourable prognosis of NPM1-mt/FLT3-ITD negative patients might be explained by a higher bax/bcl-2 ratio...
  66. ncbi request reprint Monitoring of minimal residual disease in acute myeloid leukemia
    Francesco Buccisano
    Department of Biopatologia e Diagnostica per Immagini, Fondazione Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Curr Opin Oncol 21:582-8. 2009
    ..In the present review we will focus on the use of MPFC for monitoring of MRD, addressing the main technical and clinical issues...
  67. ncbi request reprint Apoptosis and immaturity in acute myeloid leukemia
    Maria Ilaria Del Principe
    Cattedra di Ematologia, Universita Tor Vergata, Roma, Italy
    Hematology 10:25-34. 2005
    ..e. CDDOMe, bcl-2 antisense oligonucleotides, CEP-701, etc), confirming the key role of apoptotic mechanisms on the outcome of AML patients...
  68. ncbi request reprint Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow
    Giuseppe Avvisati
    Hematology, Università Campus Bio Medico, 83 Via Emilio Longoni, 00155 Rome, Italy
    Blood 100:3141-6. 2002
    ..0001) and increasing age (P =.0251). These results indicate that anthracycline monochemotherapy with IDA favorably influences the EFS of patients with newly diagnosed hypergranular APL...
  69. ncbi request reprint Late relapses in acute promyelocytic leukaemia
    Roberto Latagliata
    Dipartimento di Biotecnologie Umane e Ematologia, Universita La Sapienza, Roma, Italia
    Acta Haematol 117:106-8. 2007
    ..In conclusion, a late relapse occurred in a sizeable fraction of acute promyelocytic leukaemia patients: the high rate of ear involvement might be explained considering the ear as a 'disease sanctuary'...
  70. ncbi request reprint Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid
    Vincenza Martini
    Ann Hematol 86:295-7. 2007
  71. ncbi request reprint Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count
    Massimo Breccia
    Department of Cellular Biotechnologies and Haematology, University La Sapienza of Rome, Italy
    Br J Haematol 120:266-70. 2003
    ..Our findings highlight the importance of carrying out lumbar puncture in APL patients presenting with high-risk features...
  72. ncbi request reprint Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias
    Maria José Carnicer
    Department of Biopathology and Department of Laboratory Medicine PTV, University of Rome Tor Vergata, Italy
    Clin Chim Acta 365:342-5. 2006
    ..The regulation of gamma-glutamylcysteine synthetase (gamma-GCS) is one of the major determinants of GSH homeostasis. The aim of our study was to investigate gamma-GCS gene expression in patients affected by acute myeloid leukemia (AML)...
  73. ncbi request reprint Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
    Brunangelo Falini
    Institute of Hematology, University of Perugia, Perugia, Italy
    N Engl J Med 352:254-66. 2005
    ..Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein...
  74. ncbi request reprint A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia
    Elena Belloni
    IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
    Genes Chromosomes Cancer 41:272-7. 2004
    ..This study lends further support to the hypothesis that gene disruption resulting in either loss of function or haploinsufficiency may be relevant in acute myeloid leukemia pathogenesis...
  75. doi request reprint Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
    Daniela Cilloni
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy
    Haematologica 93:921-4. 2008
    ..WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified...
  76. ncbi request reprint Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: multiinstitutional laboratory trial
    Pascual Bolufer
    Molecular Biology, Department of Medical Biopathology, Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
    Clin Chem 50:1088-92. 2004
  77. ncbi request reprint PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia
    Enrico Tiacci
    Institutes of Hematology and Internal Medicine, University of Perugia, Perugia, Italy
    Cancer Res 64:7399-404. 2004
    ..e. the aberrant expression of B-cell genes...
  78. pmc The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
    Min Sup Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 455:813-7. 2008
    ....
  79. ncbi request reprint 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes
    Elena Belloni
    IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
    Genes Chromosomes Cancer 42:320-5. 2005
    ..Thus, our data extend the involvement of FGFR1 in EMS and lend support to the concept that there is a precise correlation between genotype and phenotype in this disease...
  80. ncbi request reprint Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    Blood 105:3019-25. 2005
    ....
  81. ncbi request reprint Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia
    Miguel A Sanz
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Oncologist 10:806-14. 2005
    ....
  82. ncbi request reprint Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
    ..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
  83. ncbi request reprint PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors
    Saverio Minucci
    European Institute of Oncology, Department of Experimental Oncology, Milan, Italy
    Blood 100:2989-95. 2002
    ..This model system faithfully reproduces the main characteristics of human APL and represents a versatile tool for the in vitro and in vivo study of mechanisms of leukemogenesis and the design of protocols for differentiation treatment...
  84. ncbi request reprint Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells
    Rania T Awwad
    Department of Biochemistry and Molecular Biology, The George Washington University Medical Center, Ross Building, Room 533, 2300 Eye Street, NW, Washington, DC, 20037, USA
    Ann Hematol 87:195-203. 2008
    ..This suggests that BP1 may be part of a pathway involved in resistance to therapy. Taken together, our data suggest that BP1 is a potential therapeutic target in APL...
  85. ncbi request reprint Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome
    Massimo Breccia
    Leuk Lymphoma 48:833-4. 2007
  86. ncbi request reprint Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias
    Daniela Cilloni
    Blood 102:2705-6. 2003